Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

MLTX vs PRAX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

PRAX Wins Head-to-Head Institutional Verdict (3–1 across 6 Pillars · 4–2 Matrix Metrics)

PRAX Overall Winner 6-Pillar Tally: MLTX 1 – 3 PRAX (2 Tie) Matrix Metrics: MLTX 2 – 4 PRAX

As of Nov 16, 2026, Praxis Precision Medicines, Inc. (PRAX) is the stronger overall head-to-head candidate over MoonLake Immunotherapeutics Class A (MLTX) in the Tradestie Institutional Equity Comparison Engine, winning 4–2 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). MLTX carries a Unified Composite Score of 38.3/100 (SELL) at $11.85 (N/M Forward P/E, 0.0% operating margin), whereas PRAX carries 34.6/100 (SELL) at $309.08 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While MLTX currently prints a higher short-term Unified Composite Score (38.3/100 SELL vs. PRAX 34.6/100 SELL), PRAX captures the overall institutional head-to-head verdict (4–2 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+1349.1% vs. +0.0% YoY).
  • Defensive Composite Rating Caution: Although PRAX compares more favorably head-to-head, both MLTX (38.3/100 SELL) and PRAX (34.6/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: MLTX is currently in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 49.5); meanwhile PRAX trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 53.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MLTX vs PRAX
MLTX NASDAQ
MoonLake Immunotherapeutics Class A Ordinary Shares
Pharmaceutical Preparations
$11.85
-5.2% 1D
Market Cap $1.1B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.61β · 90% Vol
Unified Composite Score
38.3 / 100 SELL
Tech 32.0 Fund 44.0 Flow 75.0 Mom 50.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -11.8%) with fading momentum, RSI 50
RSI-14: 49.5 · SMA20: $11.93 · SMA50: $11.82
PRAX NASDAQ Head-to-Head Winner
Praxis Precision Medicines, Inc. Common Stock
Pharmaceutical Preparations
$309.08
-5.81% 1D
Market Cap $9.1B
TTM Revenue $7.5M
Forward P/E N/M
Beta / 30D Vol 1.79β · 93% Vol
Unified Composite Score
34.6 / 100 SELL
Tech 15.0 Fund 37.0 Flow 71.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 54
RSI-14: 53.6 · SMA20: $289.18 · SMA50: $289.00

6-Pillar Scorecard Institutional Category Breakdown (MLTX 1 – 3 PRAX)

Columns: Metric · MLTX · PRAX
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale PRAX
Revenue Growth (YoY) +0.0% +1349.1%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $7.5M
Market Cap $1.1B $9.1B
3. Profitability & Quality PRAX
Gross Margin N/A N/A
Operating Margin 0.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -81.5% -44.8%
4. Balance Sheet & Cash Flow MLTX
Cash Generation (TTM) -$244M -$324M
Cash Flow Margin N/A N/A
Net Cash / Leverage $278M Net Cash $361M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning PRAX
Options Structure Phase BREAKDOWN CONSOLIDATION
Current IV / %ile 111.8% (7th %ile) 74.2% (4th %ile)
Put/Call OI Skew N/A 1.23x (Put-Skewed)
OBV Trend / Tech Phase ACCUMULATION · Distribution ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MLTX (2) vs PRAX (4)
Institutional Metric MLTX PRAX Criterion Row Edge
Market Capitalization
Scale
$1.1B $9.1B Larger Scale PRAX
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +1349.1% Higher Growth PRAX
Operating Margin (TTM)
Profitability
0.0% 0.0% Higher Margin Tie
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-81.5% -44.8% Higher ROE PRAX
52-Week Range Position
Momentum
17% ($9–$23) 64% ($160–$393) Stronger Trend PRAX
Beta / 30D Volatility
Risk Regime
1.61β · 90% Vol 1.79β · 93% Vol Lower Realized Risk MLTX
Unified Institutional Score
Composite Signal
38.3 / 100 (SELL) 34.6 / 100 (SELL) Higher Composite MLTX
Trailing 12M Revenue (USD)
Operating Scale
N/A $7.5M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$244M ($278M Net Cash) -$324M ($361M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PRAX +3.77 pp
MLTX: +24.08% · PRAX: +27.85%
3M Horizon PRAX +11.05 pp
MLTX: -27.48% · PRAX: -16.43%
6M Horizon PRAX +24.35 pp
MLTX: -27.92% · PRAX: -3.57%
1Y Horizon PRAX +79.21 pp
MLTX: -5.65% · PRAX: +73.56%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MLTX vs PRAX. Trailing 12-month operating profitability (MLTX 0.0% vs PRAX 0.0%) and valuation multiples (MLTX N/M vs PRAX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

MLTX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-81.5% · N/M
PRAX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$7.5M
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-44.8% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MLTX BREAKDOWN
103d in phase · OBV ACCUMULATION
Current IV 111.8%
IV Percentile 7th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow ACCUMULATION
Exact MLTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
PRAX CONSOLIDATION
67d in phase · OBV ACCUMULATION
Current IV 74.2%
IV Percentile 4th %ile
Put/Call OI Skew 1.23x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact PRAX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MLTX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.1B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
PRAX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $9.1B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ MLTX vs PRAX Key Questions & Quantitative Answers

As of Nov 16, 2026, Praxis Precision Medicines, Inc. (PRAX) is the stronger overall head-to-head candidate over MoonLake Immunotherapeutics Class A (MLTX) in the Tradestie Institutional Equity Comparison Engine, winning 4–2 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). MLTX carries a Unified Composite Score of 38.3/100 (SELL) at $11.85 (N/M Forward P/E, 0.0% operating margin), whereas PRAX carries 34.6/100 (SELL) at $309.08 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While MLTX currently prints a higher short-term Unified Composite Score (38.3/100 SELL vs. PRAX 34.6/100 SELL), PRAX captures the overall institutional head-to-head verdict (4–2 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+1349.1% vs. +0.0% YoY). Defensive Composite Rating Caution: Although PRAX compares more favorably head-to-head, both MLTX (38.3/100 SELL) and PRAX (34.6/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: MLTX is currently in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 49.5); meanwhile PRAX trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 53.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

PRAX leads the Growth & Scale pillar: MLTX posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with PRAX at +1349.1% YoY revenue growth and +0.0% YoY earnings growth on $7.5M TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, MLTX generates N/A in USD-normalized revenue versus $7.5M for PRAX. In operating R&D and SG&A reinvestment, MLTX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for PRAX.

MLTX and PRAX trade at balanced relative valuation multiples. MLTX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas PRAX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MLTX (-81.5% ROE) versus PRAX (-44.8% ROE) capital efficiency.

In options market volatility and institutional positioning, MLTX carries 111.8% implied volatility (7th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.61β · 90% Vol realized risk). By comparison, PRAX carries 74.2% implied volatility (4th %ile, Compressed (<25th %ile)), a 1.23x (Put-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.79β · 93% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

MoonLake Immunotherapeutics Class A Ordinary Shares (MLTX) Research Suite

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.